This data supports clinical observations that the combination of tamoxifen with everolimus has therapeutic benefit in patients with ER+ breast cancer and can re-sensitize AI-resistant breast cancer to endocrine therapy. This evidence concerns the gene ESR1 and breast carcinoma.